Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-335155
Filing Date
2026-08-05
Accepted
2026-08-05 16:15:47
Documents
66
Period of Report
2026-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q elvn-20260630.htm   iXBRL 10-Q 3034791
2 EX-3.1 elvn-ex3_1.htm EX-3.1 137047
3 EX-31.1 elvn-ex31_1.htm EX-31.1 16289
4 EX-31.2 elvn-ex31_2.htm EX-31.2 16274
5 EX-32.1 elvn-ex32_1.htm EX-32.1 10404
6 EX-32.2 elvn-ex32_2.htm EX-32.2 10394
7 GRAPHIC img116145094_0.jpg GRAPHIC 551118
  Complete submission text file 0001193125-26-335155.txt   11428642

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20260630.xsd EX-101.SCH 1013389
70 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20260630_htm.xml XML 1782972
Mailing Address 205 PARK ROAD BURLINGAME CA 94010
Business Address 205 PARK ROAD BURLINGAME CA 94010 650-547-5814
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39247 | Film No.: 261243748
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)